Alesta Therapeutics Raises €65M in Series A Funding

▤ Summary

Alesta Therapeutics, a Leiden, the Netherlands-based biotechnology company focused on developing transformative small molecule therapies for rare diseases, raised €65M in Series A funding. The round was led by Frazier Life Sciences and Droia Ventures, with participation from Novartis Venture Fund, RTW Investments, RV Invest, Thuja Capital and SSI Strategy. Alesta Therapeutics is biotechnology company committed to developing novel oral small molecule therapies for underserved rare diseases. Its lead asset, ALE1, is being developed for hypophosphatasia (HPP), a rare genetic disorder with significant unmet needs. Alesta is also advancing ALE2, a candidate to treat Charcot-Marie-Tooth (CMT) disease.

▦ Linked Companies